Design and development of novel therapeutics for coronary heart disease treatment based on cholesteryl ester transfer protein inhibition – in silico approach

References

• Amin, S. A., Adhikari, N., Gayen, S., & Jha, T. (2018). Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: A predictive approach combining comparative validated multiple molecular modelling techniques. Journal of Biomolecular Structure and Dynamics, 36(3), 590–608. doi:10.1080/07391102.2017.1288659
   PubMed Web of Science ®Google Scholar
• Amin, S. A., Adhikari, N., Gayen, S., & Jha, T. (2019). Reliable structural information for rational design of benzoxazole type potential cholesteryl ester transfer protein (CETP) inhibitors through multiple validated modelling techniques. Journal of Biomolecular Structure and Dynamics. doi:10.1080/07391102.2018.1552895
   Web of Science ®Google Scholar
• Amin, S. A., Bhattacharya, P., Basak, S., Gayen, S., Nandy, A., & Saha, A. (2017). Pharmacoinformatics study of Piperolactam A from Piper betle root as new lead for non steroidal anti fertility drug development. Computational Biology and Chemistry, 67, 213–224. doi:10.1016/j.compbiolchem.2017.01.004
   PubMed Web of Science ®Google Scholar
• Arakawa, M., Hasegawa, K., & Funatsu, K. (2007). The recent trend in QSAR modeling – Variable selection and 3D-QSAR methods. Current Computer Aided-Drug Design, 3(4), 254–262. doi:10.2174/157340907782799417
   Web of Science ®Google Scholar
• Barter, P. J., Brewer, H. B., Jr, Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003). Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 23(2), 160–167. doi:10.1161/01.ATV.0000054658.91146.64
   PubMed Web of Science ®Google Scholar
• Barter, P., & Rye, K. A. (2011). Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now? Trends in Pharmacological Sciences, 32(12), 694–699. doi:10.1016/j.tips.2011.07.004
   PubMed Web of Science ®Google Scholar
• Barter, P. J., & Rye, K.-A. (2016). New era of lipid-lowering drugs. Pharmacological Reviews, 68(2), 458–475. doi:10.1124/pr.115.012203
   PubMed Web of Science ®Google Scholar
• Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., … Tropsha, A. (2014). QSAR modeling: Where have you been? Where are you going to? Journal of Medicinal Chemistry, 57(12), 4977–5010. doi:10.1021/jm4004285
   PubMed Web of Science ®Google Scholar
• Choi, H. Y., Hafiane, A., Schwertani, A., & Genest, J. (2017). High-density lipoproteins: Biology, epidemiology, and clinical management. Canadian Journal of Cardiology, 33(3), 325–333. doi:10.1016/j.cjca.2016.09.012
   PubMed Web of Science ®Google Scholar
• Cramer, R. D. (2012). The inevitable QSAR renaissance. Journal of Computer-Aided Molecular Design, 26(1), 35–38. doi:10.1007/s10822-011-9495-0
   PubMed Web of Science ®Google Scholar
• Di Bartolo, B. A., & Nicholls, S. J. (2017). Anacetrapib as a potential cardioprotective strategy. Drug Design, Development and Therapy, 11, 3497–3502.
   PubMed Web of Science ®Google Scholar
• Dudek, A. Z., Arodz, T., & Gálvez, J. (2006). Computational methods in developing quantitative structure-activity relationships (QSAR): A review. Combinatorial Chemistry & High Throughput Screening, 9(3), 213–228. doi:10.2174/138620706776055539
   PubMed Web of Science ®Google Scholar
• Duivenvoorden, R., & Fayad, Z. A. (2012). Safety of CETP inhibition. Current Opinion in Lipidology, 23(6), 518–524. doi:10.1097/MOL.0b013e32835916b3
   PubMed Web of Science ®Google Scholar
• Ekins, S., Mestres, J., & Testa, B. (2007). In silico pharmacology for drug discovery: Methods for virtual ligand screening and profiling. British Journal of Pharmacology, 152(1), 9–20. doi:10.1038/sj.bjp.0707305
   PubMed Web of Science ®Google Scholar
• Filippatos, T. D., Klouras, E., Barkas, F., & Elisaf, M. (2016). Cholesteryl ester transfer protein inhibitors: Challenges and perspectives. Expert Review of Cardiovascular Therapy, 14(8), 953–962. doi:10.1080/14779072.2016.1189327
   PubMed Web of Science ®Google Scholar
• Gadaleta, D., Mangiatordi, G. F., Catto, M., Carotti, A., & Nicolotti, O. (2016). Applicability domain for QSAR models: Where theory meets reality. International Journal of Quantitative Structure-Property Relationships, 1(1), 45–63. doi:10.4018/IJQSPR.2016010102
   Google Scholar
• Gaikwad, R., Ghorai, S., Amin, S. A., Adhikari, N., Patel, T., Das, K., … Gayen, S. (2018). Monte Carlo based modelling approach for designing and predicting cytotoxicity of 2-phenylindole derivatives against breast cancer cell line MCF7. Toxicology in Vitro, 52, 23–32. doi:10.1016/j.tiv.2018.05.016
   PubMed Web of Science ®Google Scholar
• Gálvez, J., & García-Doménech, R. (2010). On the contribution of molecular topology to drug design and discovery. Current Computer-Aided Drug Design, 6(4), 252–268.
   PubMed Web of Science ®Google Scholar
• Gautier, T., Masson, D., & Lagrost, L. (2016). The potential of cholesteryl ester transfer protein as a therapeutic target. Expert Opinion on Therapeutic Targets, 20(1), 47–59. doi:10.1517/14728222.2015.1073713
   PubMed Web of Science ®Google Scholar
• Ghosh, R. K., & Ghosh, S. M. (2012). Current status of CETP inhibitors in the treatment of hyperlipidemia: An update. Current Clinical Pharmacology, 7(2), 102–110.
   PubMedGoogle Scholar
• Gramatica, P. (2007). Principles of QSAR models validation: Internal and external. QSAR & Combinatorial Science, 26(5), 694–701. doi:10.1002/qsar.200610151
   Google Scholar
• Halperin, I., Ma, B., Wolfson, H., & Nussinov, R. (2002). Principles of docking: An overview of search algorithms and a guide to scoring functions. Proteins, 47(4), 409–443. doi:10.1002/prot.10115
   PubMed Web of Science ®Google Scholar
• Jain, S., Amin, S. A., Adhikari, N., Jha, T., & Gayen, S. (2019). Good and bad molecular fingerprints for human rhinovirus 3C protease inhibition: Identification, validation, and application in designing of new inhibitors through Monte Carlo-based QSAR study. Journal of Biomolecular Structure and Dynamics. doi:10.1080/07391102.2019.1566093
   Web of Science ®Google Scholar
• Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery, 3(11), 935–949. doi:10.1038/nrd1549
   PubMed Web of Science ®Google Scholar
• Kosmas, C. E., Dejesus, E., Rosario, D., & Vittorio, T. J. (2016). CETP inhibition: Past failures and future hopes. Clinical Medicine Insights: Cardiology, 10, 37–42.
   PubMed Web of Science ®Google Scholar
• Kumar, P., & Kumar, A. (2018). Monte Carlo method based QSAR studies of Mer kinase inhibitors in compliance with OECD principles. Drug Research, 68(4), 189–195. doi:10.1055/s-0043-119288
   Web of Science ®Google Scholar
• Lin, L. I. (1989). A concordance correlation coefficient to evaluate reproducibility. Biometrics, 45(1), 255–268. doi:10.2307/2532051
   PubMed Web of Science ®Google Scholar
• Linsel-Nitschke, P., & Tall, A. R. (2005). HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nature Reviews Drug Discovery, 4(3), 193–205. doi:10.1038/nrd1658
   PubMed Web of Science ®Google Scholar
• Liu, P., & Long, W. (2009). Current mathematical methods used in QSAR/QSPR studies. International Journal of Molecular Sciences, 10(5), 1978–1998. doi:10.3390/ijms10051978
   PubMed Web of Science ®Google Scholar
• McLain, J. H., Alsterda, A. J., & Arora, R. R. (2017). Cholesteryl ester transfer protein inhibitors: Trials and tribulations. Journal of Cardiovascular Pharmacology and Therapeutics, 22(2), 99–104.
   PubMed Web of Science ®Google Scholar
• Mondal, C., Halder, A. K., Adhikari, N., & Jha, T. (2013). Cholesteryl ester transfer protein inhibitors in coronary heart disease: Validated comparative QSAR modeling of N,N-disubstituted trifluoro-3-amino-2-propanols. Computers in Biology and Medicine, 43(10), 1545–1555. doi:10.1016/j.compbiomed.2013.07.034
   PubMed Web of Science ®Google Scholar
• Ojha, P. K., & Roy, K. (2011). Comparative QSARs for antimalarial endochins: Importance of descriptor thinning and noise reduction prior to feature selection. Chemometrics and Intelligent Laboratory Systems, 109(2), 146–161. doi:10.1016/j.chemolab.2011.08.007
   Web of Science ®Google Scholar
• Ojha, P. K., Mitra, I., Das, R. N., & Roy, K. (2011). Further exploring rm2 metrics for validation of QSPR models. Chemometrics and Intelligent Laboratory Systems, 107(1), 194–205. doi:10.1016/j.chemolab.2011.03.011
   Web of Science ®Google Scholar
• Pérez González, M., Terán, C., Saíaz-Urra, L., & Teijeira, M. (2008). Variables selection methods in QSAR: An overview. Current Topics in Medicinal Chemistry, 8(18), 1606–1627. doi:10.2174/156802608786786552
   PubMed Web of Science ®Google Scholar
• Perkins, R., Fang, H., Tong, W., & Welsh, W. J. (2003). Quantitative structure-activity relationship methods: Perspectives on drug discovery and toxicology. Environmental Toxicology and Chemistry, 22(8), 1666–1679. doi:10.1897/01-171
   PubMed Web of Science ®Google Scholar
• Rader, D. J., Alexander, E. T., Weibel, G. L., Billheimer, J., & Rothblat, G. H. (2009). The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. Journal of Lipid Research, 50(Supplement), S189–S194. doi:10.1194/jlr.R800088-JLR200
   PubMedGoogle Scholar
• Rosenson, R. S., Brewer, H. B., Barter, P. J., Björkegren, J. L. M., Chapman, M. J., Gaudet, D., … Hegele, R. A. (2018). HDL and atherosclerotic cardiovascular disease: Genetic insights into complex biology. Nature Reviews Cardiology, 15(1), 9–19. doi:10.1038/nrcardio.2017.115
   PubMed Web of Science ®Google Scholar
• Roy, K., Das, R. N., Ambure, P., & Aher, R. B. (2016). Be aware of error measures. Further studies on validation of predictive QSAR models. Chemometrics and Intelligent Laboratory Systems, 152, 18–33. doi:10.1016/j.chemolab.2016.01.008
   Web of Science ®Google Scholar
• Roy, P. P., Leonard, J. T., & Roy, K. (2008). Exploring the impact of size of training sets for the development of predictive QSAR models. Chemometrics and Intelligent Laboratory Systems, 90(1), 31–42. doi:10.1016/j.chemolab.2007.07.004
   Web of Science ®Google Scholar
• Schaefer, E. J., & Asztalos, B. A. (2007). Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. The American Journal of Cardiology, 100(11), S25–S31. doi:10.1016/j.amjcard.2007.08.010
   Web of Science ®Google Scholar
• Schwartz, G. G. (2012). New horizons for cholesterol ester transfer protein inhibitors. Current Atherosclerosis Reports, 14(1), 41–48. doi:10.1007/s11883-011-0217-9
   PubMed Web of Science ®Google Scholar
• Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., … Wright, R. S. (2012). Effects of dalcetrapib in patients with a recent acute coronary syndrome. New England Journal of Medicine, 367(22), 2089–2099. doi:10.1056/NEJMoa1206797
   PubMed Web of Science ®Google Scholar
• Shrestha, S., Wu, B. J., Guiney, L., Barter, P. J., & Rye, K.-A. (2018). Cholesteryl ester transfer protein and its inhibitors. Journal of Lipid Research, 59(5), 772–783. doi:10.1194/jlr.R082735
   PubMed Web of Science ®Google Scholar
• Sikorski, J. A., & Connolly, D. T. (2001). The discovery of new cholesteryl ester transfer protein inhibitors. Current Opinion in Drug Discovery and Development, 4(5), 602–613.
   PubMedGoogle Scholar
• Stoičkov, V., Stojanović, D., Tasić, I., Šarić, S., Radenković, D., Babović, P., … Veselinović, A. M. (2018). QSAR study of 2,4-dihydro-3H-1,2,4-triazol-3-ones derivatives as angiotensin II AT1 receptor antagonists based on the Monte Carlo method. Structural Chemistry, 29(2), 441–449. doi:10.1007/s11224-017-1041-9
   Web of Science ®Google Scholar
• Tabeshpour, J., Sahebkar, A., Zirak, M. R., Zeinali, M., Hashemzaei, M., Rakhshani, S., & Rakhshani, S. (2018). Computer-aided drug design and drug pharmacokinetic prediction: A mini-review. Current Pharmaceutical Design, 24(26), 3014–3019.
   PubMed Web of Science ®Google Scholar
• Tall, A. R., Yvan-Charvet, L., & Wang, N. (2007). The failure of torcetrapib: Was it the molecule or the mechanism? Arteriosclerosis, Thrombosis, and Vascular Biology, 27(2), 257–260. doi:10.1161/01.ATV.0000256728.60226.77
   PubMed Web of Science ®Google Scholar
• Tardif, J.-C., Rhainds, D., Rhéaume, E., & Dubé, M.-P. (2017). CETP: Pharmacogenomics-based response to the CETP inhibitor dalcetrapib. Arteriosclerosis, Thrombosis, and Vascular Biology, 37(3), 396–400. doi:10.1161/ATVBAHA.116.307122
   PubMed Web of Science ®Google Scholar
• Terstappen, G. C., & Reggiani, A. (2001). In silico research in drug discovery. Trends in Pharmacological Sciences, 22(1), 23–26.
   PubMed Web of Science ®Google Scholar
• Thomsen, R., & Christensen, M. H. (2006). MolDock: A new technique for high-accuracy molecular docking. Journal of Medicinal Chemistry, 49(11), 3315–3321. doi:10.1021/jm051197e
   PubMed Web of Science ®Google Scholar
• Toropov, A. A., Duchowicz, P., & Castro, E. A. (2003). Structure–toxicity relationships for aliphatic compounds based on correlation weighting of local graph invariants. International Journal of Molecular Sciences, 4(5), 272–283. doi:10.3390/i4050272
   Web of Science ®Google Scholar
• Toropov, A. A., & Toropova, A. P. (2017). The index of ideality of correlation: A criterion of predictive potential of QSPR/QSAR models? Mutation Research – Genetic Toxicology and Environmental Mutagenesis, 819, 31–37. doi:10.1016/j.mrgentox.2017.05.008
   PubMed Web of Science ®Google Scholar
• Toropova, A. P., & Toropov, A. A. (2018). CORAL: Monte Carlo method to predict endpoints for medical chemistry. Mini-Reviews in Medicinal Chemistry, 18(5), 382–391. doi:10.2174/1389557517666170927154931
   PubMed Web of Science ®Google Scholar
• Toropova, M. A., Raška, I., Jr., Toropov, A. A., & Raškova, M. (2016). The utilization of the Monte Carlo technique for rational drug discovery. Combinatorial Chemistry & High Throughput Screening, 19(8), 676–687. doi:10.2174/1386207319666160725145852
   PubMed Web of Science ®Google Scholar
• Tropsha, A., & Golbraikh, A. (2007). Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Current Pharmaceutical Design, 13(34), 3494–3504.
   PubMed Web of Science ®Google Scholar
• Verma, J., Khedkar, V. M., & Coutinho, E. C. (2010). 3D-QSAR in drug design – A review. Current Topics in Medicinal Chemistry, 10(1), 95–115.
   PubMed Web of Science ®Google Scholar
• Veselinović, A. M., Toropov, A., Toropova, A., Stanković-Đorđević, D., & Veselinović, J. B. (2018). Design and development of novel antibiotics based on FtsZ inhibition – In silico studies. New Journal of Chemistry, 42(13), 10976–10982. doi:10.1039/C8NJ01034J
   Web of Science ®Google Scholar
• Veselinović, A. M., Veselinović, J. B., Živković, J. V., & Nikolić, G. M. (2015). Application of SMILES notation based optimal descriptors in drug discovery and design. Current Topics in Medicinal Chemistry, 15(18), 1768–1779.
   PubMed Web of Science ®Google Scholar
• Veselinović, J. B., Kocić, G. M., Pavic, A., Nikodinovic-Runic, J., Senerovic, L., Nikolić, G. M., & Veselinović, A. M. (2015). Selected 4-phenyl hydroxycoumarins: in vitro cytotoxicity, teratogenic effect on zebrafish (Danio rerio) embryos and molecular docking study. Chemico-Biological Interactions, 231, 167–174.
   Web of Science ®Google Scholar
• Zakiev, E., Feng, M., Sukhorukov, V., & Kontush, A. (2017). HDL-targeting therapeutics: Past, present and future. Current Pharmaceutical Design, 23(8), 1207–1215. doi:10.2174/1381612822666161027153140
   PubMed Web of Science ®Google Scholar